Evotec SE
Company Profile
Business description
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Contact
Essener Bogen 7
Manfred Eigen Campus
Hamburg22419
DEUT: +49 40560810
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
4,766
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,756.60 | 39.40 | -0.45% |
CAC 40 | 7,765.11 | 10.79 | -0.14% |
DAX 40 | 23,771.45 | 177.45 | -0.74% |
Dow JONES (US) | 42,967.62 | 101.85 | 0.24% |
FTSE 100 | 8,884.92 | 20.57 | 0.23% |
HKSE | 23,866.86 | 168.52 | -0.70% |
NASDAQ | 19,662.48 | 46.61 | 0.24% |
Nikkei 225 | 37,689.16 | 483.93 | -1.27% |
NZX 50 Index | 12,526.07 | 123.03 | -0.97% |
S&P 500 | 6,045.26 | 23.02 | 0.38% |
S&P/ASX 200 | 8,533.90 | 31.20 | -0.36% |
SSE Composite Index | 3,378.01 | 24.64 | -0.72% |